Cargando…
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite nanomedicine's remarkable potential and growth over the last three decades, its clinical benefits for cancer patients vary. Here we report a...
Autores principales: | Pérez-Medina, Carlos, Abdel-Atti, Dalya, Tang, Jun, Zhao, Yiming, Fayad, Zahi A., Lewis, Jason S., Mulder, Willem J. M., Reiner, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915130/ https://www.ncbi.nlm.nih.gov/pubmed/27319780 http://dx.doi.org/10.1038/ncomms11838 |
Ejemplares similares
-
Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
por: Zhao, Yiming, et al.
Publicado: (2016) -
A novel afterglow nanoreporter for monitoring cancer therapy
por: Liao, Shiyi, et al.
Publicado: (2022) -
Reversible Electroporation–Mediated Liposomal Doxorubicin Delivery to Tumors Can Be Monitored With (89)Zr-Labeled Reporter Nanoparticles
por: Srimathveeravalli, Govindarajan, et al.
Publicado: (2018) -
Prediction of Anti-cancer Nanotherapy Efficacy by Imaging
por: Miller, Miles A., et al.
Publicado: (2017) -
Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy
por: Nguyen, Anh, et al.
Publicado: (2020)